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Introduction {#jah32181-sec-0005}
============

The relationship between baseline levels of troponin or creatine kinase‐MB and outcomes among patients with non‐ST‐segment elevation acute coronary syndromes (NSTE ACS) is established.[1](#jah32181-bib-0001){ref-type="ref"} This relationship has not been well studied in medically managed NSTE ACS populations in the era of modern antithrombotic therapy that includes systematic use of more potent P2Y12 inhibition as a component of dual antiplatelet therapy. In addition, whether the effect of treatment with a more potent P2Y12 antagonist (eg, prasugrel versus clopidogrel) is influenced by degree of biomarker elevation, particularly among medically managed patients, is unknown. Although the relationship of troponin elevation at baseline with outcome is strong over the first 30 days post‐ACS, it becomes weaker over longer durations of follow‐up.[2](#jah32181-bib-0002){ref-type="ref"}, [3](#jah32181-bib-0003){ref-type="ref"} The TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) trial database provided the opportunity to explore these important issues in a medically managed NSTE ACS population treated with long‐term dual antiplatelet therapy.

In a substudy of TRILOGY ACS, the Platelet Function Substudy, evaluation of platelet reactivity measured by serial P2Y12 reaction unit (PRU) assessment showed more potent platelet inhibition with prasugrel compared with clopidogrel.[4](#jah32181-bib-0004){ref-type="ref"} There was no relationship between platelet reactivity and ischemic outcomes or differential treatment effect according to platelet reactivity. The relationship between peak troponin level, platelet reactivity, outcomes, and treatment effect has not been explored. The Platelet Function Substudy provided an opportunity to examine these relationships.

Methods {#jah32181-sec-0006}
=======

Data Source {#jah32181-sec-0007}
-----------

The study design and primary results of TRILOGY ACS were previously published.[5](#jah32181-bib-0005){ref-type="ref"} Briefly, TRILOGY ACS was a multinational, double‐blind, double‐dummy, randomized active controlled trial that compared the effects of prasugrel versus clopidogrel among patients with NSTE ACS who were medically managed without revascularization. The trial was conducted between June 2008 and September 2011 at 966 centers worldwide. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke at 30‐month follow‐up. The trial was approved by the institutional review board or ethics committee of all participating sites, and all participants provided written informed consent prior to enrollment. The current analyses were approved by the Duke University Medical Center Institutional Review Board with waiver of informed consent and HIPAA (Health Insurance Portability and Accountability Act of 1996) authorization.

Patient Characteristics and Study Definitions {#jah32181-sec-0008}
---------------------------------------------

TRILOGY ACS randomized 9326 patients. For this secondary analysis, we identified 6763 patients (72.5% of the intention‐to‐treat population) for whom peak troponin (T or I) data were available within 48 hours of the index event. Troponin I was used twice as often as troponin T. Patients were excluded if they had recurrent MI, bypass surgery, or percutaneous coronary intervention between the index event presentation and the reported peak cardiac troponin value. The analysis of platelet function included only patients enrolled in the Platelet Function Substudy who had peak troponin data available (n=1810/2564 \[70.6%\]).

End Points {#jah32181-sec-0009}
----------

Efficacy outcomes of interest in this secondary analysis were the following: (1) 30‐month cardiovascular death, MI, or stroke (primary efficacy end point of TRILOGY ACS); (2) 30‐month cardiovascular death or MI; (3) 30‐month rates of the individual components cardiovascular death, MI, and stroke; and (4) 30‐month all‐cause death.

Statistical Methods {#jah32181-sec-0010}
-------------------

Because multiple troponin assays were used across the 966 sites in TRILOGY ACS, we normalized site‐laboratory‐based peak troponin values as a ratio of the site‐reported upper limit of normal (ULN) for the assay used. Patients were grouped by categories of peak troponin/ULN ratio (\<1×ULN; 1 to \<3×ULN; 3 to \<5×ULN; ≥5×ULN). Peak troponin ratios were truncated to the 98th percentile for statistical analysis. For this study, peak troponin was the highest value measured within 48 hours of the index event.

Baseline patient characteristics, including demographics, clinical characteristics, GRACE (Global Registry of Acute Coronary Events) risk score, and concomitant medications at randomization, were summarized according to peak troponin ratio. The GRACE score is a risk‐stratification tool developed to estimate the risk of in‐hospital and 6‐month mortality among all patients hospitalized with ACS. The risk score was created from a risk‐prediction model developed using an international ACS registry database.[6](#jah32181-bib-0006){ref-type="ref"} Continuous variables are presented as medians (25th, 75th percentiles), and differences were compared using the Kruskal--Wallis test. Categorical variables are presented as counts (percentages), and differences were compared using the Pearson χ^2^ or Fisher exact test if cell frequencies were not sufficient.

For each ischemic outcome, the total number of events and Kaplan--Meier event rates at 30 months after randomization (95% CI) were presented according to peak troponin category. Time‐to‐event is defined as the time from randomization to the onset of the end point. Time‐to‐first‐event for a composite end point is defined as the time from randomization to the occurrence of the first event of the composite end point. Censoring rules are defined in Tables [S1](#jah32181-sup-0001){ref-type="supplementary-material"} and [S2](#jah32181-sup-0001){ref-type="supplementary-material"}. Event rates across the follow‐up period were compared using the log‐rank test.

To examine the relationship between peak troponin level and clinical outcomes, unadjusted and adjusted Cox proportional hazards regression models were developed to test the univariable and multivariable associations of continuous peak troponin ratios with each clinical outcome. TRILOGY ACS models previously built for each ischemic outcome were used to adjust for baseline characteristics and risk factors. The proportional hazards assumption was checked for each variable, and the linearity assumption was checked for each continuous variable. If the proportional hazards assumption was violated, an interaction of the variable with log‐transformed time was included in the model. If the linearity assumption was violated, a linear or restricted cubic spline was used to approximate the nonlinear relationship of the variable with the outcome.[7](#jah32181-bib-0007){ref-type="ref"} In cases where the peak troponin ratio was found to have a nonlinear relationship with a given end point, it was modeled using a linear spline with a knot point at 3.0×ULN, which was determined via numerical simulation across the range of all peak troponin ratios. For further details, please see Table [S3](#jah32181-sup-0001){ref-type="supplementary-material"}. A full description of the TRILOGY ACS adjustment models used in this analysis is provided in Data [S1](#jah32181-sup-0001){ref-type="supplementary-material"} and Table [S4](#jah32181-sup-0001){ref-type="supplementary-material"}.

The interaction between peak troponin level, study treatment (prasugrel versus clopidogrel), and ischemic outcomes was also computed. Further assessment of this relationship was completed in a subgroup of patients who underwent coronary angiography prior to randomization, eliminating those without angiographically proven coronary disease (lesion causing \>50% stenosis).

Baseline characteristics of patients in the Platelet Function Substudy sample were summarized according to peak troponin ratio category. For these patients, the unadjusted and adjusted associations of peak troponin ratio with 30‐day PRU values and the interaction with study treatment were evaluated. To gauge the strength of the linear relationship between peak troponin ratio and 30‐day PRU values, the Pearson correlation coefficient was computed and the null hypothesis of zero correlation was tested.

All analyses were conducted using SAS statistical software version 9.4 (SAS Institute, Cary, NC). A *P* value of \<0.05 (2‐sided) was considered statistically significant. No adjustments were made for multiple comparisons.

Results {#jah32181-sec-0011}
=======

Overall Study Sample {#jah32181-sec-0012}
--------------------

Baseline characteristics of the 6763 patients who had sufficient laboratory data reported to determine the peak troponin ratio at 48 hours compared with the 2563 patients who were excluded are provided in Table [S5](#jah32181-sup-0001){ref-type="supplementary-material"}. Baseline characteristics of the 6763 patients included are shown by peak troponin ratio categories in Table [1](#jah32181-tbl-0001){ref-type="table-wrap"}. Patients with peak troponin ratios \<1×ULN were younger, more often women, more often from Central/Eastern Europe, and had lower GRACE risk scores than patients in other troponin groups. Patients with ratios ≥5×ULN more frequently smoked but less often had prior MI or percutaneous coronary intervention. Diabetes mellitus prevalence, body mass index, and hemoglobin were similar across groups. Although there was a statistically significant difference in serum creatinine across troponin groups, absolute differences were small and unlikely to be clinically relevant.

###### 

Baseline Characteristics According to 48‐Hour Peak Troponin Level

                                                                  Peak Troponin Level as Ratio of ULN   *P* Value                                                            
  --------------------------------------------------------------- ------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  Demographics                                                                                                                                                               
  Age, y                                                          65.0 (58.0, 72.0)                     67.0 (58.0, 75.0)      67.0 (60.0, 75.0)      67.0 (60.0, 76.0)      \<0.001
  Age ≥75 y                                                       285/1574 (18.1%)                      301/1203 (25.0%)       156/581 (26.9%)        954/3405 (28.0%)       \<0.001
  Weight, kg                                                      75.0 (65.0, 86.0)                     75.0 (65.0, 89.0)      75.0 (65.0, 86.0)      77.0 (66.0, 89.0)      0.008
  Weight \<60 kg                                                  211/1573 (13.4%)                      191/1201 (15.9%)       78/581 (13.4%)         426/3401 (12.5%)       0.033
  Sex                                                                                                                                                                        0.004
  Female                                                          648/1574 (41.2%)                      466/1203 (38.7%)       223/581 (38.4%)        1221/3405 (35.9%)      
  Male                                                            926/1574 (58.8%)                      737/1203 (61.3%)       358/581 (61.6%)        2184/3405 (64.1%)      
  Region                                                                                                                                                                     \<0.001
  Central/Eastern Europe                                          714/1574 (45.4%)                      354/1203 (29.4%)       195/581 (33.6%)        798/3405 (23.4%)       
  East Asia                                                       180/1574 (11.4%)                      110/1203 (9.1%)        42/581 (7.2%)          246/3405 (7.2%)        
  Indian subcontinent                                             147/1574 (9.3%)                       140/1203 (11.6%)       43/581 (7.4%)          149/3405 (4.4%)        
  Latin America                                                   175/1574 (11.1%)                      142/1203 (11.8%)       61/581 (10.5%)         381/3405 (11.2%)       
  Mediterranean basin                                             103/1574 (6.5%)                       86/1203 (7.1%)         32/581 (5.5%)          318/3405 (9.3%)        
  North America                                                   132/1574 (8.4%)                       190/1203 (15.8%)       99/581 (17.0%)         821/3405 (24.1%)       
  Western Europe/Scandinavia                                      112/1574 (7.1%)                       158/1203 (13.1%)       95/581 (16.4%)         604/3405 (17.7%)       
  Rest of world                                                   11/1574 (0.7%)                        23/1203 (1.9%)         14/581 (2.4%)          88/3405 (2.6%)         
  Presentation characteristics                                                                                                                                               
  Hours from presentation to start of study drug                  83.3 (45.5, 141.4)                    109.0 (64.8, 159.2)    109.7 (69.2, 158.4)    118.0 (72.3, 165.8)    \<0.001
  Killip class II--IV on presentation                             129/1572 (8.2%)                       148/1202 (12.3%)       81/581 (13.9%)         467/3404 (13.7%)       \<0.001
  Disease classification                                                                                                                                                     \<0.001
  Unstable angina/unknown                                         1291/1574 (82.0%)                     165/1203 (13.7%)       0/581 (0.0%)           0/3405 (0.0%)          
  NSTEMI                                                          283/1574 (18.0%)                      1038/1203 (86.3%)      581/581 (100.0%)       3405/3405 (100.0%)     
  Medical history                                                                                                                                                            
  Family history of CAD                                           421/1402 (30.0%)                      361/1070 (33.7%)       162/522 (31.0%)        1064/2984 (35.7%)      0.002
  Hypertension                                                    1347/1570 (85.8%)                     991/1201 (82.5%)       491/581 (84.5%)        2720/3393 (80.2%)      \<0.001
  Hyperlipidemia                                                  925/1482 (62.4%)                      711/1164 (61.1%)       334/565 (59.1%)        2175/3304 (65.8%)      0.001
  Diabetes mellitus                                               598/1574 (38.0%)                      488/1201 (40.6%)       244/581 (42.0%)        1309/3396 (38.5%)      0.214
  Current/recent smoking[a](#jah32181-note-0003){ref-type="fn"}   268/1558 (17.2%)                      231/1192 (19.4%)       119/573 (20.8%)        826/3363 (24.6%)       \<0.001
  Prior MI                                                        697/1566 (44.5%)                      559/1194 (46.8%)       260/576 (45.1%)        1408/3366 (41.8%)      0.016
  Prior PCI                                                       521/1569 (33.2%)                      422/1196 (35.3%)       176/578 (30.4%)        795/3372 (23.6%)       \<0.001
  Prior CABG                                                      261/1572 (16.6%)                      218/1203 (18.1%)       90/580 (15.5%)         632/3390 (18.6%)       0.149
  Prior PAD                                                       92/1552 (5.9%)                        89/1175 (7.6%)         43/572 (7.5%)          302/3333 (9.1%)        0.002
  Prior atrial fibrillation                                       126/1533 (8.2%)                       106/1175 (9.0%)        50/565 (8.8%)          263/3296 (8.0%)        0.685
  Prior heart failure                                             304/1565 (19.4%)                      178/1194 (14.9%)       98/576 (17.0%)         400/3376 (11.8%)       \<0.001
  Prior stroke                                                    7/1571 (0.4%)                         4/1198 (0.3%)          4/578 (0.7%)           24/3385 (0.7%)         0.414
  Baseline risk assessment                                                                                                                                                   
  GRACE risk score                                                116.0 (101.0, 130.0)                  122.0 (106.0, 141.0)   128.0 (112.0, 147.0)   124.0 (108.0, 144.0)   \<0.001
  Body mass index, kg/m^2^                                        27.0 (24.5, 30.5)                     27.2 (24.2, 31.0)      27.2 (24.6, 30.8)      27.3 (24.4, 30.8)      0.485
  Systolic blood pressure, mm Hg                                  130.0 (120.0, 140.0)                  130.0 (117.0, 140.0)   126.0 (118.0, 138.0)   125.0 (115.0, 138.0)   \<0.001
  Heart rate, bpm                                                 68.5 (62.0, 76.0)                     69.0 (62.0, 76.0)      68.0 (60.0, 76.0)      69.0 (62.0, 76.0)      0.491
  Hemoglobin, g/dL                                                13.6 (12.6, 14.6)                     13.4 (12.3, 14.5)      13.6 (12.4, 14.7)      13.5 (12.4, 14.7)      0.104
  Serum creatinine, mg/dL                                         1.0 (0.8, 1.1)                        1.0 (0.8, 1.2)         1.0 (0.9, 1.2)         1.0 (0.8, 1.2)         \<0.001
  At randomization                                                                                                                                                           
  Treatment                                                                                                                                                                  0.323
  Prasugrel                                                       767/1574 (48.7%)                      585/1203 (48.6%)       276/581 (47.5%)        1725/3405 (50.7%)      
  Clopidogrel                                                     807/1574 (51.3%)                      618/1203 (51.4%)       305/581 (52.5%)        1680/3405 (49.3%)      
  Clopidogrel strata                                                                                                                                                         \<0.001
  No clopidogrel                                                  123/1574 (7.8%)                       36/1203 (3.0%)         22/581 (3.8%)          92/3405 (2.7%)         
  Clopidogrel started in hospital ≤72 hours                       905/1574 (57.5%)                      798/1203 (66.3%)       421/581 (72.5%)        2759/3405 (81.0%)      
  Home clopidogrel                                                546/1574 (34.7%)                      369/1203 (30.7%)       138/581 (23.8%)        554/3405 (16.3%)       
  Prerandomization procedures                                                                                                                                                
  Angiography performed                                           555/1574 (35.3%)                      568/1203 (47.2%)       256/581 (44.1%)        1941/3405 (57.0%)      \<0.001
  Concomitant medications at randomization                                                                                                                                   
  Aspirin daily dose                                                                                                                                                         
  \<100 mg                                                        470/1574 (29.9%)                      406/1203 (33.7%)       182/581 (31.3%)        1116/3405 (32.8%)      0.112
  100 to 250 mg                                                   943/1574 (59.9%)                      628/1203 (52.2%)       308/581 (53.0%)        1658/3405 (48.7%)      \<0.001
  \>250 mg                                                        86/1574 (5.5%)                        89/1203 (7.4%)         56/581 (9.6%)          396/3405 (11.6%)       \<0.001
  β‐Blocker                                                       1248/1574 (79.3%)                     947/1203 (78.7%)       468/581 (80.6%)        2753/3405 (80.9%)      0.339
  ACE‐I/ARB                                                       1173/1574 (74.5%)                     883/1203 (73.4%)       446/581 (76.8%)        2635/3405 (77.4%)      0.018
  Statin                                                          1287/1574 (81.8%)                     1016/1203 (84.5%)      482/581 (83.0%)        2945/3405 (86.5%)      \<0.001
  Proton pump inhibitor                                           355/1574 (22.6%)                      308/1203 (25.6%)       185/581 (31.8%)        982/3405 (28.8%)       \<0.001

Data presented as n/N (%) or median (25th, 75th percentile). ACE‐I/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; bpm, beats per minute; CABG, coronary artery bypass graft; CAD, coronary artery disease; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction; NSTEMI, non‐ST‐segment elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; ULN, upper limit of normal.

Smoking within 30 days of randomization.

Ischemic Outcomes According to Peak Troponin {#jah32181-sec-0013}
--------------------------------------------

Table [2](#jah32181-tbl-0002){ref-type="table-wrap"} shows the number of 30‐month ischemic outcome events and Kaplan--Meier event rates across peak troponin categories. Figure [1](#jah32181-fig-0001){ref-type="fig"} displays corresponding Kaplan--Meier event rate curves. Trends for increasing event rates with increasing peak troponin ratios were statistically significant for all end points. The relationship was linear for 30‐month all‐cause mortality but appeared to increase and then plateau at peak troponin ratios ≥3×ULN for the composite end points. The greatest difference in event rates was between peak troponin ratios \<1×ULN and any peak troponin ratio ≥1×ULN during early follow‐up. Through 30 months, event rates for patients with peak troponin ratios ≥5×ULN were more than twice as high as rates for patients with peak troponin ratios \<1×ULN.

###### 

Thirty‐Month Ischemic Event Rates According to 48‐Hour Peak Troponin Level

                                        Peak Troponin Level as Ratio of ULN   *P* Value[a](#jah32181-note-0005){ref-type="fn"}                                           
  ------------------------------------- ------------------------------------- -------------------------------------------------- ------------------- ------------------- ---------
  Cardiovascular death, MI, or stroke                                                                                                                                    \<0.001
  No. of events                         118                                   172                                                104                 607                 
  KM event rate (95% CI)                11.3 (9.1--13.5)                      18.4 (15.3--21.4)                                  26.6 (20.9--32.3)   25.1 (23.0--27.1)   
  Cardiovascular death                                                                                                                                                   \<0.001
  No. of events                         62                                    80                                                 41                  297                 
  KM event rate (95% CI)                5.8 (4.2--7.3)                        9.6 (7.0--12.3)                                    10.8 (6.6--15.0)    12.8 (11.1--14.4)   
  Myocardial infarction                                                                                                                                                  \<0.001
  No. of events                         63                                    102                                                72                  364                 
  KM event rate (95% CI)                6.4 (4.6--8.1)                        10.4 (8.4--12.4)                                   17.6 (13.1--22.0)   15.6 (13.8--17.3)   
  Cardiovascular death or MI                                                                                                                                             \<0.001
  No. of events                         111                                   157                                                97                  569                 
  KM event rate (95% CI)                10.6 (8.5--12.8)                      16.8 (13.8--19.8)                                  25.0 (19.4--30.6)   23.5 (21.4--25.5)   
  Stroke                                                                                                                                                                 0.005
  No. of events                         11                                    22                                                 8                   67                  
  KM event rate (95% CI)                1.2 (0.4--2.0)                        2.8 (1.5--4.1)                                     1.8 (0.5--3.2)      3.3 (2.4--4.3)      
  All‐cause death                                                                                                                                                        \<0.001
  No. of events                         83                                    102                                                60                  362                 
  KM event rate (95% CI)                7.3 (5.7--9.0)                        11.8 (9.1--14.5)                                   14.7 (10.3--19.0)   14.8 (13.2--16.5)   

KM indicates Kaplan--Meier; MI, myocardial infarction; No., number; ULN, upper limit of normal.

Two‐sided *P* value based on the log‐rank test.

![Cumulative Kaplan--Meier estimates of 30‐month ischemic outcomes by 48‐hour peak troponin elevation. For visualization of the numerical results presented in Table [2](#jah32181-tbl-0002){ref-type="table-wrap"}, Kaplan--Meier failure curves are presented for each efficacy end point. See Table [2](#jah32181-tbl-0002){ref-type="table-wrap"} for relevant log‐rank *P* values. MI indicates myocardial infarction; ULN, upper limit of normal.](JAH3-6-e005334-g001){#jah32181-fig-0001}

Table [3](#jah32181-tbl-0003){ref-type="table-wrap"} displays unadjusted and adjusted hazard ratios for 30‐month ischemic outcomes per unit increase in peak troponin ratio, modeled as a linear spline. The graphic representation of this relationship for the primary efficacy end point is displayed in Figure [S1](#jah32181-sup-0001){ref-type="supplementary-material"}A and [S1](#jah32181-sup-0001){ref-type="supplementary-material"}B. In unadjusted analyses, increases in peak troponin ratio were strongly associated with each outcome up to 3×ULN; beyond this, the risk of ischemic events remained relatively constant as peak troponin ratios increased. Results were consistent after adjustment for baseline characteristics, except that the association with cardiovascular death was no longer significant. Note, the upper segment of the troponin linear spline (ratios \>3×ULN) is not presented in Table [3](#jah32181-tbl-0003){ref-type="table-wrap"} as all associations with outcomes are nonsignificant.

###### 

Unadjusted and Adjusted Hazard Ratios for 30‐Month Ischemic Outcomes According to 48‐Hour Peak Troponin Elevation

                                     Unadjusted HR (95% CI)[a](#jah32181-note-0007){ref-type="fn"}   Adjusted HR (95% CI)[a](#jah32181-note-0007){ref-type="fn"}   Peak Troponin×Treatment Interaction *P* Value
  ---------------------------------- --------------------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------
  Cardiovascular death, MI, stroke   1.350 (1.263--1.442)                                            1.182 (1.066--1.311)                                          0.483
  Cardiovascular death or MI         1.347 (1.257--1.443)                                            1.183 (1.062--1.318)                                          0.433
  Cardiovascular death               1.291 (1.175--1.419)                                            1.090 (0.942--1.263)                                          0.371
  Myocardial infarction              1.411 (1.292--1.541)                                            1.238 (1.081--1.419)                                          0.413
  Stroke                             1.387 (1.136--1.695)                                            0.998 (0.996--1.001)[b](#jah32181-note-0008){ref-type="fn"}   0.191
  All‐cause mortality                1.282 (1.179--1.393)                                            1.001 (1.000--1.001)[b](#jah32181-note-0008){ref-type="fn"}   0.234

HR indicates hazard ratio; MI, myocardial infarction.

Per 1 unit increase in peak troponin/upper limit of normal ratio.

Peak troponin elevation modeled linearly as the assumption of linearity was satisfied.

Table [3](#jah32181-tbl-0003){ref-type="table-wrap"} also shows that there were no statistically significant interactions between peak troponin ratio and study treatment for any of the ischemic outcomes. The graphic representation of this relationship is displayed in Figure [S2](#jah32181-sup-0001){ref-type="supplementary-material"}. In a subgroup analysis assessing this relationship among patients with angiographically proven coronary disease, the interaction between peak troponin ratio, study treatment, and either combined end point or all‐cause mortality also lacked statistical significance. These results remained unchanged after adjustment for time from patient presentation to administration of study drug.

Peak Troponin and Platelet Function {#jah32181-sec-0014}
-----------------------------------

Among patients enrolled in the TRILOGY ACS Platelet Function Substudy, 1810 (70.6%) had necessary measurements to compute peak troponin/ULN ratios. Baseline characteristics by peak troponin ratio category are shown in Table [S6](#jah32181-sup-0001){ref-type="supplementary-material"}. Compared with other groups, patients with peak troponin ratios \<1xULN were younger, more often from Central/Eastern Europe, and less likely to be current/prior smokers or have a family history of coronary artery disease or hyperlipidemia. Additionally, they were less likely to have undergone angiography prior to randomization. Diabetes mellitus prevalence was similar across groups.

As displayed in Figure [2](#jah32181-fig-0002){ref-type="fig"}, there was no relationship between peak troponin and PRU among patients with angiographically proven coronary artery disease. Results remain unchanged even after adjustment for age group (≥75 years versus \<75 years), clopidogrel stratum at randomization, randomized treatment assignment, and time from patient presentation to start of study drug.

![Forty‐eight‐hour peak troponin ratio and 30‐day platelet reactivity unit (PRU). For patients enrolled in the Platelet Function Substudy, a box plot is used to assess the unadjusted association of peak troponin elevation with 30‐day PRU, as well as the interaction with study treatment (*P*\<0.001). ULN indicates upper limit of normal.](JAH3-6-e005334-g002){#jah32181-fig-0002}

Discussion {#jah32181-sec-0015}
==========

This analysis of TRILOGY ACS demonstrated that among NSTE ACS patients selected for medical management, including dual antiplatelet therapy with a P2Y12 antagonist, there was a graded relationship of increasing peak troponin with long‐term ischemic events. Event rates at 30 months for patients with troponin ≥5×ULN were more than twice those for patients with peak troponin \<1×ULN. There was no apparent incremental benefit of treatment with prasugrel versus clopidogrel according to peak troponin ratio among medically managed patients with NSTE ACS.

Peak Troponin and Long‐Term Outcomes {#jah32181-sec-0016}
------------------------------------

Since the introduction of troponin testing in the early 1990s, its role has evolved from MI diagnosis to include risk stratification following ACS. It is known from previous analyses, including FRISC (Fragmin during Instability in Coronary Artery Disease) and TACTICS‐TIMI 18 (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy---Thrombolysis in Myocardial Infarction 18) that patients with NSTE ACS who have troponin elevations above the ULN at admission are at higher risk for death and recurrent ischemic events.[2](#jah32181-bib-0002){ref-type="ref"}, [8](#jah32181-bib-0008){ref-type="ref"}, [9](#jah32181-bib-0009){ref-type="ref"} Furthermore, through additional analyses of trials such as GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIa, there is a well‐characterized relationship between the magnitude of troponin elevation and outcomes among patients with NSTE ACS.[1](#jah32181-bib-0001){ref-type="ref"} Troponin elevation can also identify which patients are most likely to benefit from aggressive antithrombotic therapy and an early invasive strategy.[8](#jah32181-bib-0008){ref-type="ref"}, [9](#jah32181-bib-0009){ref-type="ref"}

Recently, a secondary analysis of the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, a study designed to examine the effect of vorapaxar (a protease‐activated receptor‐1 antagonist) versus placebo in NSTE ACS, identified a differential relationship between the magnitude of troponin elevation and 2‐year mortality among patients treated with and without revascularization. In a subset of patients included in TRACER who did not undergo revascularization, increasing levels of peak cardiac troponin were associated with increasing long‐term mortality (*P*=0.001). This relationship was not observed in those who underwent revascularization (*P*=0.23).[10](#jah32181-bib-0010){ref-type="ref"}

The graded relationship of increasing peak troponin with ischemic events that we observed was consistent with this observation and prior studies evaluating troponin elevation as a prognostic indicator among patients with NSTE ACS. However, TRILOGY ACS provided the unique opportunity to establish this relationship over a long‐term (30‐month) follow‐up period among patients who were medically managed with P2Y12 inhibitor therapy. Thus, the results of this analysis extend our understanding of the relationship of troponin with risk to long‐term follow‐up in the important population of medically managed NSTE ACS patients in the contemporary era of more potent P2Y12 inhibitor therapy. Our analyses demonstrate that despite advances in other medical therapy acutely and in secondary prevention, higher peak troponin values portend worse ischemic outcomes.

Peak Troponin and Effect of More Potent Antiplatelet Therapy {#jah32181-sec-0017}
------------------------------------------------------------

Substudies of several randomized clinical trials showed that the treatment effect of glycoprotein IIb/IIIa antagonists was amplified among patients with baseline troponin elevation, but there was no evident benefit among those without.[11](#jah32181-bib-0011){ref-type="ref"}, [12](#jah32181-bib-0012){ref-type="ref"}, [13](#jah32181-bib-0013){ref-type="ref"} These findings were consistent across studies despite significant differences in patient populations, highlighting the importance of troponin elevation in identifying high‐risk patients who may benefit from more potent antiplatelet therapy.[11](#jah32181-bib-0011){ref-type="ref"} Given these observations and our results correlating troponin and rates of adverse cardiovascular events, it might be anticipated that higher‐risk medically managed patients with greater peak troponin levels would also benefit preferentially from more potent antiplatelet therapy. However, we observed no such interaction of peak troponin level with more potent dual antiplatelet therapy among patients assigned to prasugrel compared with clopidogrel. This was consistent among the subset of patients with angiographically proven coronary disease who were medically managed in TRILOGY ACS. Thus, it is unlikely that inclusion of patients with troponin elevation unrelated to atherosclerotic coronary disease significantly influenced our analysis.

A number of considerations may contribute to our observations. Because this is a secondary analysis, it was not powered to detect an effect of more potent P2Y12 inhibition according to peak troponin values. Further, whereas the PARAGON‐B (Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B) study assessed a glycoprotein IIb/IIIa inhibitor (steady‐state platelet aggregation inhibition \>90%) versus placebo, neither prasugrel (50%) nor clopidogrel (30%) achieve that level of platelet aggregation inhibition, and they were compared head‐to‐head instead of against placebo.[14](#jah32181-bib-0014){ref-type="ref"}, [15](#jah32181-bib-0015){ref-type="ref"} Together these features of trial design may have contributed to the differential findings. Additionally, participants in TRILOGY ACS were randomized to prasugrel or clopidogrel ≈4.5 days after their index clinical event and could be enrolled up to 10 days after the index event.[5](#jah32181-bib-0005){ref-type="ref"} It is possible that the benefit of more potent antiplatelet therapy may be related to the timing of therapy initiation relative to myocardial ischemia onset (which was much earlier in PARAGON‐B), and particularly that patients with completed infarction by this time point may not benefit from more potent antiplatelet therapy. Additionally, prior evaluations of more potent antiplatelet therapies primarily focused on patients who underwent an invasive treatment strategy. It is possible that the benefit of more potent antiplatelet therapy seen in prior studies may have been derived from reduced periprocedural adverse ischemic outcomes. Finally, it is possible that bleeding complications may have attenuated the benefit of more potent antiplatelet therapy.

Peak Troponin and Platelet Reactivity {#jah32181-sec-0018}
-------------------------------------

A substudy of TRILOGY ACS evaluated the effects of prasugrel and clopidogrel on serial PRU assessments. This analysis revealed lower platelet reactivity with prasugrel compared with clopidogrel; however, there was no difference in ischemic outcomes by treatment assignment.[4](#jah32181-bib-0004){ref-type="ref"}, [5](#jah32181-bib-0005){ref-type="ref"} Our exploratory analysis of the TRILOGY ACS Platelet Function Substudy revealed that the effect of treatment on platelet inhibition (as assessed by 30‐day PRU values) did not vary substantially based on peak troponin value.

Strengths and Limitations {#jah32181-sec-0019}
-------------------------

This secondary analysis of TRILOGY ACS demonstrates a novel correlation between troponin elevation and prognosis in a study sample selected for medical management of NSTE ACS. One of the strengths of our analysis is that it used data collected as part of a large, multinational, randomized trial, which enhances data consistency and eliminates bias in the assessment of overall treatment effects. Because of the large number of subjects, the results are statistically robust. However, because these results are drawn from a patient population selected for a randomized clinical trial, they may not be generalizable to the broader population of medically managed patients in general practice. Troponin values used for our analysis were collected up to 48 hours after presentation, consistent with contemporary clinical practice. It is possible that by limiting our analysis to values within 48 hours of presentation, a higher peak value could have been missed, but this rule was applied consistently to all patients. Peak troponin data within 48 hours were not available in about 25% of study participants, eliminating this group from our analysis. Although there were differences between those included or not, most were modest and would not be expected to alter the relationships we observed (Table [S5](#jah32181-sup-0001){ref-type="supplementary-material"}). Troponin assays were not standardized across participating sites. Thus, they reflect a wide variety of individual assays with variable assay performance characteristics, and potentially varying site‐specific ULNs for the same assay. However, this reflects the state of actual clinical practice, and we attempted to account for this by normalizing the reported values using a ratio of the reported value to the ULN reported for the assay. This variability and resultant "noise" introduced would be expected to result in an underestimation of the relationship between increasing troponin level and outcomes. Additionally, it is possible that some patients with elevated troponin levels who were included in TRILOGY ACS did not have significant coronary artery disease. In this case, the true association of troponin with long‐term ischemic outcomes may have been underestimated. Of the patients who underwent angiography, however, very few had absence of obstructive coronary disease, and when we excluded those patients from our analyses, there were no differences in our findings. Although designed to evaluate medically managed patients, a small number of patients (7.1%) underwent postindex revascularization at a median of 120.5 days after the index event. Because of the infrequency of downstream revascularization in our study sample and that it occurred late relative to the time of troponin sampling, we believe the commitment to an initial medical management strategy was met and that it is unlikely that our results were significantly affected. Finally, it is possible that because we defined peak troponin using values collected within 48 hours after the index event, the true peak troponin value was missed. However, it is important to note that the impact of missing the true peak would tend to underestimate the relationship between peak troponin level and adverse outcomes. Despite its limitations, our analysis shows the prognostic importance of higher levels of troponin for long‐term outcomes among medically managed patients with NSTE ACS, even in the setting of treatment with modern, potent antiplatelet agents, and the effect is not related to the degree of platelet inhibition as assessed by the P2Y12 assay.

Conclusion {#jah32181-sec-0020}
==========

Among NSTE ACS patients selected for medical management, there was a graded relationship of increasing peak troponin with long‐term ischemic events, but no heterogeneity of treatment effect for prasugrel versus clopidogrel (clinical or PRU‐based) according to 48‐hour peak troponin level.
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**Figure S1.** A, Estimated spline transformation and 95% CI for the relationship of troponin elevation and unadjusted rates of cardiovascular death, MI, or stroke through 30 months. B, Estimated spline transformation and 95% CI for the relationship of troponin elevation and adjusted rates of cardiovascular death, MI, or stroke through 30 months.
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